An experimental once-a-day tablet has slashed ‘bad’ cholesterol levels by approximately 60%, potentially saving millions from heart attacks and strokes.
The pill has recently passed a large phase three trial, marking the most significant drop in LDL cholesterol ever recorded with an oral drug since the introduction of statins.
The medication, known as enlicitide, operates similarly to potent cholesterol-lowering injections but in tablet form. Researchers suggest it could significantly simplify life for patients who struggle to meet cholesterol targets even when taking high-dose statins.
Lead investigator Dr Ann Marie Navar, a cardiologist at UT Southwestern Medical Centre, stated: « Fewer than half of patients with established atherosclerotic cardiovascular disease currently reach LDL cholesterol goals.
« An oral therapy this effective has the potential to dramatically improve our ability to prevent heart attacks and strokes on a population level. »
As reported by The New England Journal of Medicine, nearly 3,000 individuals participated in the trial, the majority of whom were already on statins but still had elevated LDL.
After 24 weeks, those taking enlicitide had about 60% lower LDL than those on placebo, and these benefits remained consistent over a year.
LDL cholesterol accumulates in arteries gradually, leading to heart attacks and strokes.
A once-daily tablet could eliminate a significant obstacle to treatment and broaden availability, particularly for those who find it difficult to visit clinics or store and administer injectable medications.
Numerous patients, including those working extended hours, struggle to reach their targets even with the most potent statins – whether due to adverse reactions, drug limitations, or the additional inconvenience of injections.
Enlicitide remains under investigation and will require regulatory authorisation before physicians in the UK can prescribe it.
An additional trial is currently in progress to establish whether the substantial LDL reductions result in fewer heart attacks and strokes, rather than merely improved laboratory results.
Source link
